IBM shares are declining approximately 5% in Wednesday's session, pulling back from a prior close of $320.42. The primary driver is profit-taking after an extraordinary two-week rally that saw shares surge more than 25%, fueled by a $10 billion quantum computing investment and a bullish Barclays initiation at Overweight with a $350 price target.
BX shares are down approximately 4.3%–5.2% in premarket trading on June 3, 2026, moving from a prior close of $114.91 to approximately $109.98. The primary catalyst is a Bloomberg News report revealing that Partners Group, a leading Swiss private equity firm, restricted investor withdrawals from one of its funds, reigniting sector-wide fears about liquidity pressures in private markets.
UP Fintech reported total revenue of $154.9 million for the first quarter ended March 31, 2026, marking a 26.3% increase year-over-year. Total net revenues reached $136.7 million, up 27.1% from the prior-year period.
BW LPG Limited reported Q1 2026 profit attributable to equity holders of US$164 million, up sharply from US$46 million a year earlier, with earnings per share of US$1.08. Time charter equivalent (TCE) income reached US$55,500 per available day, exceeding the company’s guidance of US$54,000 per day.
Signet Jewelers reported first quarter Fiscal 2027 earnings per share of $1.56, beating the consensus estimate of $1.38 by $0.18. Revenue reached $1.55 billion, up 0.8% year over year and in line with expectations.
GitLab reported Q1 fiscal 2027 revenue of $264.16 million, exceeding consensus estimates of $254.23 million. Non-GAAP earnings per share came in at $0.23, beating analyst expectations of $0.20 by $0.03.
Net sales reached $1.56 billion, a 15% increase year-over-year, exceeding analyst forecasts of approximately $1.52 billion. Adjusted earnings per share came in at $0.60, significantly beating consensus estimates of $0.29 to $0.31.
Third quarter fiscal 2026 sales reached a record $995.1 million, up 5.8% year over year. Adjusted diluted earnings per share rose 7.1% to $1.06, beating the consensus estimate of $1.05.
Net sales rose 11.1% to $3.16 billion, driven by 5.3% comparable sales growth, new stores, and the Space NK acquisition. Diluted EPS increased 15.5% to $7.74, exceeding analyst expectations.
Dollar General reported first-quarter fiscal 2026 net sales of $10.8 billion, up 3.4% year-over-year, with same-store sales rising 2.0%. Diluted EPS reached $2.00, a 12.4% increase from $1.78 in the prior-year quarter and above analyst expectations.
Total revenue reached $3.0 billion, up 31% year over year, including contributions from recent acquisitions. Next-Generation Security ARR grew 60% year over year to $8.1 billion, boosted by $1.6 billion from CyberArk and Chronosphere.
XMTR shares fell approximately 9.99% intraday, closing the prior session at $95.25 and trading as low as $85.73. The primary catalyst was Xometry’s announcement of a $225 million underwritten public offering of Class A common stock priced at $85 per share.
Greenwich LifeSciences, Inc. (GLSI) shares fell sharply, declining approximately 17.56% intraday.
EDIT shares fell approximately 14.52% as of the latest available price, closing the prior session at $3.34. The primary catalyst was investor reaction to the company’s recent public stock offering announcement, raising dilution concerns.
Verra Mobility Corporation (VRRM) shares fell approximately 16.05% from the prior session close of $4.89 to the latest available price near $4.105. The decline followed reports of multiple securities fraud investigations targeting the company and its investors.
VLGEA shares plunged more than 19% following the release of fiscal third-quarter results. Primary catalyst was the company's earnings report showing modest sales growth but pressure on margins and profitability metrics.
Virgin Galactic Holdings, Inc. (SPCE) shares plunged 36.77% intraday as the stock traded near $4.76 after closing the prior session at $7.52.
ABVX shares fell sharply, declining approximately 44.56% from the prior session's close of $129.69. The primary catalyst was a cancer signal identified in the ABTECT Phase 3 trial for obefazimod in ulcerative colitis, overshadowing positive efficacy results.
PRAX shares are down approximately 9% in premarket trading on June 2, 2026, from the prior session close of $335.16 to an implied level near $304.99. The primary catalyst is the after-hours announcement on June 1 that the Phase 2/3 POWER1 clinical trial evaluating vormatrigine in adults with focal onset seizures failed to meet its primary endpoint — the percent change in monthly seizure frequency from baseline.